Research activities

Synthesis of platinum complexes, stability studies, HPLC

CV

Since 2012: ICT Prague, Drugs and Biomaterials PhD program
2010 - 2012: ICT Prague, Drug Production master degree program
Thesis title: Preparation of Pt(II)-complexis with potential cytostatic activity
Since 2008: Member of the research team at the Department of Organic Technology, ICT Prague
2007 - 2010: ICT Prague, Drug Production and Synthesis bachelor degree program
Thesis title: Degradation stability study of picoplatin, cytostatic drug of the 4th generation

Publications

1. Housková, J.; Hrdá, M.; Syslová, K.; Novotný, P.; Kačer, P. HPLC Method for Monitoring of Degradation Products in Picoplatin Stability Study. Chromatographia 2011, 73 (1), 131-135.
DOI: 10.1007/s10337-011-1938-1

Conferences

2012: The Merck Prize competition (talk) – Prague, Czech Republic
2011: Student scientific conference (poster) – ICT Prague, Czech Republic
2010: Student scientific conference (talk) – ICT Prague, Czech Republic
2009: Student scientific conference (talk) – ICT Prague, Czech Republic

Current research project

The work is oriented toward preparation of platinum complexes with potential biological activity – analogues with the (1R,2R)-diaminocyclohexane (DACH) ligand, i.e. Oxaliplatin, and analogues of amminedichloro (2-methylpyridine)platinous komplex, i.e. Picoplatin as novel patent-free cytostatics that may be suitable for further application in the pharmaceutical industry. The aim is to prepare such analogues which showed identical or higher cytostatic activity and lower side effects, especially given by their low solubility in water. The first phase is focused on optimization of the preparation procedures of individual complexes and their analytical determination by HPLC with UV/Vis or MS detection. Purification of the crude product is also crucial. More attention is paid to the preparation of samples suitable for diffraction analysis (X-ray monocrystal diffraction and X-ray powder diffraction). Finally, the prepared complexes are tested in selected tumor cell lines in the XTT test and potentially positive tested candidates are brought in for the toxicity test (LD50 determination).